Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6813-6820

  Xiao, Qi Wang ^a   Yong, Qiang Zhu ^a   Lui, Karen S ^a   Cai, Qi ^a   Lu, Ping ^a   Poon, Ronnie T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CISPLATIN; POLO LIKE KINASE 1; PROTEIN CDC25A; UNCLASSIFIED DRUG; CDC25A PROTEIN, HUMAN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIVISION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; METASTASIS; MITOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CYCLE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; CARCINOMA, HEPATOCELLULAR; CDC25 PHOSPHATASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DOWN-REGULATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 58149214374     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0626     Document Type: Article

References (28)

1. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signaling pathways and their organization in space and time. DNA Repair (Amst) 2004;3:997-1007.
2. Li L, Zou L. Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells. J Cell Biochem 2005;94:298-306.
3. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
4. Syljuase RG. Checkpoint adaptation in human cells. Oncogene 2007;26:5833-9.
5. Neely KE, Piwnica-Worms H. Cdc25A regulation: to destroy or not to destroy - is that the only question? Cell Cycle 2003;2:473-8.
6. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006;18:185-91.
7. Agner J, Falck J, Lukas J, Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 2005;302:162 -9.
8. Galaktionov K, Lee AK, Eckstein J, et al. CDC25 phosphatases as potential human oncogenes. Science 1995;269:1575-7.
9. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004;11:1043-51.
10. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint controla nd cancer. Cancer Cell 2003;3:421-9.
11. Myer DL, Bahassi el M , Stambrook PJ. The Plk3-25 circuit. Oncogene 2005;24:299-305.
12. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000;2:672-6.
13. Bahassi el M, Conn CW, Myer DL, et al. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 2002;21:6633-40.
14. Xie S, Wu H, Wang Q, et al. Genotoxic stressinduced activation of Plk3 is partly mediated by Chk2. Cell Cycle 2002;1:424-9.
15. van Vugt MA, Bras A, Medema RH. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res 2005;65:7037-40.
16. 2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 2006;66:10253-7.
17. Hu L, Wen JM, Sham JS, et al. Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004;23:298-302.
18. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 1999;81:814-21.
19. Li Y, Tian B,Yang J, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004;130:460-8.
20. Ito Y, Yoshida H, Tomoda C, et al. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett 2005;229:291-7.
21. Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, Fan ST. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res 2005;11:483-9.
22. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging handbook: TNM classification of malignant tumors. 6th ed. NewYork: Springer; 2002.
23. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-9.
24. Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549-61.
25. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-8.
26. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005;24:2844-59.
27. Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr Biol 2007;17:R280-3.
28. de Carcer G, de Castro IP, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007;14:969-85.